J&J says FDA approves Rybrevant in combination with standard of care chemo

Johnson & Johnson announced that the U.S. Food and Drug Administration approved RYBREVANT in combination with standard of care chemotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. “RYBREVANT plus chemotherapy may address the most common mechanisms of treatment resistance to third generation EGFR TKIs, such as osimertinib, in the first line,” said Martin Dietrich, M.D., Ph.D., Oncologist, Cancer Care Centers of Brevard. “This multitargeted combination extended progression-free survival and improved overall response compared to chemotherapy alone, offering an important and effective new second-line option for patients.”